In a regulatory filing, Keros Therapeutics disclosed that its director Carl Gordon sold 250K shares of common stock on August 13th in a total transaction size of $11.0M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics Updates Investors with New Presentation
- Keros Therapeutics reports Q2 EPS ($1.25), consensus ($1.23)
- Keros Therapeutics Reports Second Quarter 2024 Financial Results
- Keros Therapeutics initiated with an Outperform at Oppenheimer
- 3 Best Stocks to Buy Now, 6/18/2024, According to Top Analysts